INGENESIS delivers comprehensive pharmaceutical CDMO services — from pre-formulation and formulation development to GMP manufacturing, regulatory support, and ICH stability studies.
INGENESIS LLC is a pharmaceutical contract development and manufacturing organization (CDMO) dedicated to advancing drug products from concept through commercialization. Our team of regulatory and scientific experts brings decades of experience across FDA drug approval pathways, ICH guidelines, and cGMP manufacturing standards.
From API characterization and early-stage feasibility through GMP manufacturing and regulatory submission, INGENESIS provides the full spectrum of pharmaceutical development services.
Integrated, milestone-driven development programs that compress timelines from discovery to clinical stage with dedicated project management.
Learn MoreCustom synthesis, process chemistry, API characterization, salt and polymorph screening, and impurity synthesis for small molecule drugs.
Learn MoreComprehensive physicochemical characterization including solubility profiling, pKa, polymorphism, hygroscopicity, and excipient compatibility.
Learn MoreQbD-driven formulation design for tablets, capsules, liquids, semi-solids, and injectables — from proof-of-concept through commercial readiness.
Learn MoreUSP/ICH-compliant method development, validation, and transfer with full 21 CFR Part 11 data integrity for IND, NDA, and ANDA submissions.
Learn MoreAPI-sparing small batch manufacturing for preclinical toxicology, PK studies, and Phase I/II clinical trial materials with fast turnaround.
Learn MoreICH Q1A–Q1F compliant stability studies with controlled climatic chambers for all ICH zones and continuous 24/7 environmental monitoring.
Learn MoreCDMO Services — cGMP clinical and commercial-scale manufacturing with complete QA batch release, documentation, and regulatory filing support.
Learn MoreWe combine deep scientific expertise with regulatory mastery to give you a competitive edge at every stage of development.
Deep expertise in IND, NDA, ANDA, 510(k), PMA, and BLA pathways with former FDA experience on our team.
PhD-led scientific teams with specialization in formulation, analytical chemistry, and process development.
CDMO Services manufacturing with Class 100,000 cleanrooms, state-of-the-art analytical instrumentation.
Comprehensive QMS with 21 CFR Part 11 compliance, full data integrity, and robust change control.
Dedicated project managers, transparent communication, and real-time project dashboards for every client.
Serving pharma, biotech, and device companies across North America, Europe, and Asia-Pacific markets.
Our regulatory affairs team has direct experience across all major FDA approval mechanisms for drugs, devices, and combination products.
A trusted CDMO partner delivering science-driven pharmaceutical development and manufacturing excellence.
INGENESIS LLC was founded by pharmaceutical scientists and regulatory professionals with a shared vision: to create a CDMO that clients could trust not just for technical execution, but as a true strategic partner in drug development.
Our team brings together expertise in formulation science, analytical chemistry, regulatory affairs, quality assurance, and clinical operations — offering an integrated capability that eliminates the inefficiencies of working with multiple service providers.
We serve pharmaceutical, biotechnology, and medical device clients ranging from virtual start-ups to established commercial organizations, supporting programs from early discovery through post-approval lifecycle management.
To accelerate the development of safe, effective pharmaceutical products through integrated scientific expertise, regulatory excellence, and innovative manufacturing solutions that serve patients worldwide.
To be the most trusted pharmaceutical development partner, recognized globally for scientific innovation, regulatory mastery, and unwavering commitment to quality and patient safety.
Unwavering ethical standards in every scientific decision, regulatory submission, and client interaction.
Quality built into every process, not inspected in — from experimental design through final product release.
Continuously investing in new technologies, methodologies, and scientific approaches to solve complex drug delivery challenges.
Treating every client program as our own — with proactive communication, transparent timelines, and shared accountability.
INGENESIS offers end-to-end pharmaceutical development and manufacturing services. Our integrated capabilities allow seamless transitions between development phases, reducing timelines and accelerating your path to market.
Integrated, milestone-driven development programs compressing timelines from discovery to IND filing.
Learn MoreCustom synthesis, process chemistry, and salt/polymorph screening for small molecule APIs.
Learn MorePhysicochemical characterization providing the scientific foundation for rational formulation design.
Learn MoreQbD-driven dosage form development across all routes of administration and delivery technologies.
Learn MoreICH/USP compliant method development, validation, and testing supporting all regulatory filings.
Learn MoreFlexible small-batch manufacturing for preclinical and early clinical trial material needs.
Learn MoreAll ICH climatic zones with real-time, accelerated, and stress testing programs for global submissions.
Learn MoreCDMO Services — cGMP clinical and commercial-scale contract manufacturing with full regulatory documentation.
Learn MoreReach out to our scientific team to discuss your program and how we can help accelerate your development timeline.
Whether you are at the early discovery stage or preparing for a regulatory submission, our scientific and regulatory experts are ready to discuss how INGENESIS can support your specific needs.
Build your career at the intersection of science, innovation, and regulatory excellence. We are always looking for talented pharmaceutical professionals.
At INGENESIS, our team members are at the heart of every drug development success. We offer a collaborative environment where scientific curiosity is rewarded, professional growth is supported, and the work you do directly impacts patient outcomes worldwide.
Work alongside PhD scientists and regulatory experts on cutting-edge pharmaceutical development programs.
Structured mentorship programs, continuing education support, and clear advancement pathways at every level.
Cross-functional teams that value every perspective. Your ideas are heard, tested, and implemented here.
Competitive compensation, health and dental insurance, 401(k) matching, PTO, and flexible work arrangements.
Your work supports drug development programs that help patients in markets across North America, Europe, and Asia.
Conference sponsorships, professional certifications, journal access, and in-house technical training programs.
We are currently hiring across formulation science, analytical chemistry, regulatory affairs, and quality assurance. All positions are based in Rockville, MD unless otherwise noted.
We are always interested in hearing from talented pharmaceutical scientists, engineers, and regulatory professionals. Send your resume and a brief introduction to careers@ingenesisllc.com and we will keep your information on file for future openings.
Stay current with the latest news, scientific publications, industry events, and technical resources from INGENESIS.
A deep dive into FDA's updated nitrosamine impurity guidance, including risk assessment frameworks, analytical testing requirements, and acceptable intake limits for drug products.
Read ArticleMeet the INGENESIS team at CPhI Americas, the premier pharmaceutical industry exhibition in North America. Schedule a meeting to discuss your development program.
Learn MoreComprehensive guide covering stability chamber selection, protocol design, data analysis, and shelf-life estimation methods compliant with ICH guidelines.
Download PDFHow Quality by Design and structured DoE approaches improve formulation robustness, reduce development timelines, and strengthen regulatory filings.
Read ArticleINGENESIS scientists will present original research on bioavailability enhancement strategies for BCS Class II/IV compounds at the AAPS Annual Meeting.
View DetailsOn-demand webinar covering FDA regulatory pathways for combination products, primary mode of action determinations, and submission strategy for combination product developers.
Watch NowInsights from the INGENESIS scientific and regulatory team — covering formulation science, analytical chemistry, and FDA regulatory strategy.
Practical frameworks for nitrosamine impurity risk assessment, analytical testing, and acceptable intake limit calculations for IND and NDA submissions.
Read ArticleHow structured QbD and DoE methodologies improve formulation robustness, reduce development timelines, and strengthen CTD Module 3 filings.
Read ArticleA step-by-step guide to developing discriminating dissolution methods for ER/CR tablets and capsules, from apparatus selection to biorelevant media design.
Read ArticleHow to identify and use published literature and previously approved drug data to support a 505(b)(2) NDA, including bridging studies and labeling considerations.
Read ArticleComparing amorphous solid dispersions, nanosizing, lipid-based systems, and co-crystal approaches for poorly soluble APIs in early clinical development.
Read ArticlePractical guidance on ALCOA+ principles, electronic record management, audit trail requirements, and common FDA data integrity observations in CDMO settings.
Read ArticleMeet the INGENESIS team at industry conferences, exhibitions, and scientific symposia throughout the year.
White papers, webinar recordings, regulatory guides, and scientific presentations from the INGENESIS team — free to download.
Comprehensive guide to stability chamber selection, protocol design, data analysis, and shelf-life estimation methods aligned with ICH Q1A through Q1F guidelines.
Download PDFDecision framework for evaluating CDMO capabilities, quality systems, regulatory track record, and fit-for-purpose assessment across development stages.
Download PDFOverview of critical pre-formulation studies — solubility, pKa, polymorphism, hygroscopicity, and excipient compatibility — and their role in IND package preparation.
Download PDFCovers FDA combination product regulation, primary mode of action determinations, Request for Designation process, and submission strategy for combination product developers.
Watch NowPractical walkthrough of analytical requirements for IND submissions including drug substance characterization, drug product specifications, and analytical method validation expectations.
Watch NowStep-by-step implementation of QbD principles including Target Product Profile, Critical Quality Attributes, risk assessment, and Design of Experiments for solid oral dosage forms.
Watch NowComplete CMC checklist for Phase I IND submissions covering drug substance, drug product, and analytical sections with FDA expectations and common deficiency pitfalls.
Download GuidePractical implementation guide for ICH Q3D elemental impurity controls, including risk assessment templates, permitted daily exposure calculations, and ICP-MS testing strategy.
Download GuideStep-by-step guide for successful technology transfer from development to GMP manufacturing, covering validation protocols, scale-up considerations, and regulatory documentation.
Download Guide